Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 9, 2007, Pages 656-658

  Steinherz, Peter G ^a   Meyers, Paul A ^a   Steinherz, Laurel J ^a   Jeha, Sima ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ALL; AML; Clofarabine; Complete remission; Multiply relapsed ALL; Multiply relapsed AML; Purine nucleoside analog; Refractory leukemia

Indexed keywords

ANTIBIOTIC AGENT; ASPARAGINASE; BUSULFAN; CLOFARABINE; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; THIOTEPA; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADENINE NUCLEOTIDES; ADOLESCENT; ARABINONUCLEOSIDES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MALE; RECURRENCE; REMISSION INDUCTION;

EID: 34548392229     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318142b94b     Document Type: Article

References (17)

1. The Leukemia & Lymphoma Society. Facts 2003: Leukemia, Lymphoma, Myeloma. White Plains: The Leukemia & Lymphoma Society; 2003:1-21.
2. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
3. Sadowitz PD, Smith SD, Shuster J, et al. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1993;81:602-609.
4. Buchanan GR, Rivera GK, Pollock BH, et al. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group study. Cancer. 2000;88:1166-1174.
5. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004;103:784-789.
6. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379-2386.
7. Jeha S, Gaynor PS, Razzouk B, et al. Phase 2 study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Onc. 2006;24:1917-1923.
8. Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7:3580-3589.
9. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003;9:6335-6342.
10. Parker WB, Shaddix SC, Rose LM, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)adenine, 2-chloro-9-(2-deoxy-2, 2-difluoro-β-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol. 1999;55:515-520.
11. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991;51:2386-2394.
12. Parker WB, Bapat AR, Shen JX, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34:485-491.
13. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res. 1995;55:2847-2852.
14. Xie C, Plunkett W. Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine. Cancer Res. 1996;56:3030-3037.
15. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000;96:3537-3543.
16. Kantarjian H, Gandhi V, Kozuch P, et al. Phase 1 clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21:1167-1173.
17. Weitman S, Ochoa S, Sullivan J, et al. Pediatric Phase II Cancer Chemotherapy Trials: a Pediatric Oncology Group Study. J Ped Hem Oncol. 1997;19:187-191.